SCHEMBL3768038

SCHEMBL3768038

Cc1cc(C)nc(NC(=O)c2cn3cc(N(C)C)ccc3n2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.49
MAPT P10636 4/20 0.48
LMNA P02545 2/20 0.48
SORT1 Q99523 1/20 0.46
CHRNB2 P17787 1/20 0.43
CHRNB4 P30926 1/20 0.43
CHRNA3 P32297 1/20 0.43
CHRNA4 P43681 1/20 0.43
NPC1 O15118 5/20 0.42
RAB9A P51151 5/20 0.42
ALOX15 P16050 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
SMN1; SMN2 Q16637 5/20 0.41
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 3/20 0.41
PKM P14618 2/20 0.41
GBA1 P04062 1/20 0.41
MAPK1 P28482 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3766225 0.86 GRM5 (0.56) MAPTSORT1NPC1RAB9ASMN1; SMN2
SCHEMBL3774161 0.85 SORT1 (0.49) LMNASORT1NPC1RAB9ASMN1; SMN2
SCHEMBL3777070 0.82 KDM4E (0.54) MAPTLMNANPC1RAB9ACYP1A2
SCHEMBL3771091 0.81 NPC1 (0.41) MAPTLMNANPC1RAB9AALOX15
SCHEMBL3778748 0.79 EGLN1 (0.42) SORT1EGLN1
SCHEMBL3779529 0.79 NPC1 (0.42) MAPTLMNANPC1RAB9AALOX15
SCHEMBL3766242 0.79 ALDH1A1 (0.44) MAPTLMNANPC1RAB9AALOX15
SCHEMBL3780549 0.79 NR4A2 (0.42) NPC1RAB9AALOX15EGLN1ADORA2A
SCHEMBL3770857 0.79 EGLN1 (0.39) MAPTLMNANPC1RAB9ASMN1; SMN2
SCHEMBL3371180 0.79 KCNK3 (0.53) MAPTLMNANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317673-A1 N-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2010-12-16 US claimed
US-20100317673-A1 N-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317673-A1 N-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION IDH2, GLS, IDH1 LCK 1706/4885MAPT 3010/4885LMNA 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.